Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE 1, OPEN LABEL, CROSSOVER STUDY TO EVALUATE PALATABILITY AND RELATIVE BIOAVAILABILITY OF TWO PEDIATRIC MICROSPHERE FORMULATIONS OF CRIZOTINIB IN HEALTHY PARTICIPANTS

Next Previous
Trial Profile

A PHASE 1, OPEN LABEL, CROSSOVER STUDY TO EVALUATE PALATABILITY AND RELATIVE BIOAVAILABILITY OF TWO PEDIATRIC MICROSPHERE FORMULATIONS OF CRIZOTINIB IN HEALTHY PARTICIPANTS

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 Aug 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Crizotinib (Primary) ; Crizotinib; Esomeprazole
  • Indications Anaplastic large cell lymphoma; Bladder cancer; Glioblastoma; Neuroblastoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Prostate cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Pfizer

Most Recent Events

  • 13 Nov 2019 Status changed from recruiting to completed.
  • 30 Jul 2019 Planned End Date changed from 8 Oct 2019 to 16 Oct 2019.
  • 30 Jul 2019 Planned primary completion date changed from 8 Oct 2019 to 16 Oct 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top